Comprehensive Stock Comparison
Compare Soleno Therapeutics, Inc. (SLNO) vs Ascendis Pharma A/S (ASND) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | SLNO | Lower P/E (9.3x vs 49.1x) |
| Quality / Margins | SLNO | 11.0% net margin vs ASND's -31.7% |
| Stability / Safety | ASND | Beta 0.24 vs SLNO's 0.68 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ASND | +49.1% vs SLNO's -20.0% |
| Efficiency (ROA) | SLNO | 3.7% ROA vs ASND's -17.5%, ROIC 15.6% vs -69.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Soleno Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare diseases. It currently generates no revenue from commercial sales — its financial runway comes from equity financing and potential milestone payments — with its lead candidate in Phase III trials for Prader-Willi syndrome. The company's competitive advantage lies in its focused expertise on rare disease therapeutics and its lead candidate's potential to address a significant unmet medical need in Prader-Willi syndrome.
Ascendis Pharma is a biopharmaceutical company developing innovative therapies using its proprietary TransCon technology platform. It generates revenue primarily from sales of its approved growth hormone therapy SKYTROFA and through strategic partnerships — with future revenue expected from its pipeline of endocrinology and oncology treatments. The company's key competitive advantage is its TransCon platform, which enables sustained release of therapeutics with improved pharmacokinetics and reduced dosing frequency.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SLNO leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). ASND leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
ASND is the larger business by revenue, generating $718M annually — 3.8x SLNO's $190M. SLNO is the more profitable business, keeping 11.0% of every revenue dollar as net income compared to ASND's -31.7%.
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| RevenueTrailing 12 months | $190M | $718M |
| EBITDAEarnings before interest/tax | $61M | -$119M |
| Net IncomeAfter-tax profit | $21M | -$228M |
| Free Cash FlowCash after capex | $47M | $43M |
| Gross MarginGross profit ÷ Revenue | +50.9% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +32.4% | -19.0% |
| Net MarginNet income ÷ Revenue | +11.0% | -31.7% |
| FCF MarginFCF ÷ Revenue | +24.6% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +41.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +163.0% | +15.6% |
Valuation Metrics
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| Market CapShares × price | $145,692 | $14.3B |
| Enterprise ValueMkt cap + debt − cash | -$67M | $14.6B |
| Trailing P/EPrice ÷ TTM EPS | 100.18x | -54.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.28x | 49.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -1.11x | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 17.57x |
| Price / BookPrice ÷ Book value/share | 4.72x | — |
| Price / FCFMarket cap ÷ FCF | 0.00x | 278.56x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), SLNO scores 6/9 vs ASND's 5/9, reflecting solid financial health.
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| ROE (TTM)Return on equity | +4.6% | — |
| ROA (TTM)Return on assets | +3.7% | -17.5% |
| ROICReturn on invested capital | +15.6% | -69.1% |
| ROCEReturn on capital employed | +15.1% | -51.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$67M | $256M |
| Cash & Equiv.Liquid assets | $70M | $616M |
| Total DebtShort + long-term debt | $3M | $871M |
| Interest CoverageEBIT ÷ Interest expense | -6.60x | -0.62x |
Total Returns (with DRIP)
A $10,000 investment in ASND five years ago would be worth $14,939 today (with dividends reinvested), compared to $1,966 for SLNO. Over the past 12 months, ASND leads with a +49.1% total return vs SLNO's -20.0%. The 3-year compound annual growth rate (CAGR) favors SLNO at 56.7% vs ASND's 28.1% — a key indicator of consistent wealth creation.
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| YTD ReturnYear-to-date | -17.2% | +9.5% |
| 1-Year ReturnPast 12 months | -20.0% | +49.1% |
| 3-Year ReturnCumulative with dividends | +284.9% | +110.2% |
| 5-Year ReturnCumulative with dividends | -80.3% | +49.4% |
| 10-Year ReturnCumulative with dividends | -90.9% | +1245.8% |
| CAGR (3Y)Annualised 3-year return | +56.7% | +28.1% |
Risk & Volatility
ASND is the less volatile stock with a 0.24 beta — it tends to amplify market swings less than SLNO's 0.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASND currently trades 96.5% from its 52-week high vs SLNO's 43.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.24x |
| 52-Week HighHighest price in past year | $90.32 | $242.00 |
| 52-Week LowLowest price in past year | $32.84 | $124.06 |
| % of 52W HighCurrent price vs 52-week peak | +43.3% | +96.5% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 54.8 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 573K |
Analyst Outlook
Wall Street rates SLNO as "Buy" and ASND as "Buy". Consensus price targets imply 169.3% upside for SLNO (target: $105) vs 22.7% for ASND (target: $287).
| Metric | SLNOSoleno Therapeuti… | ASNDAscendis Pharma A… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $105.20 | $286.50 |
| # AnalystsCovering analysts | 11 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | +0.1% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | 100 | 20.37 | -79.6% |
| Ascendis Pharma A/S (ASND) | 100 | 165.23 | +65.2% |
Ascendis Pharma A/S (ASND) returned +49% over 5 years vs Soleno Therapeutics… (SLNO)'s -80%. A $10,000 investment in ASND 5 years ago would be worth $14,939 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | $1M | $190M | +13024.2% |
| Ascendis Pharma A/S (ASND) | $5M | $692M | +14917.6% |
Soleno Therapeutics, Inc.'s revenue grew from $1M (2016) to $190M (2025) — a 71.9% CAGR. Ascendis Pharma A/S's revenue grew from $5M (2016) to $692M (2025) — a 74.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -8.3% | 11.0% | +231.9% |
| Ascendis Pharma A/S (ASND) | -14.9% | -31.7% | -112.9% |
Soleno Therapeutics, Inc.'s net margin went from -8% (2016) to 11% (2025). Ascendis Pharma A/S's net margin went from -15% (2016) to -32% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -58.35 | 0.39 | +100.7% |
| Ascendis Pharma A/S (ASND) | -2.58 | -3.62 | -40.3% |
Soleno Therapeutics, Inc.'s EPS grew from $-58.35 (2016) to $0.39 (2025). Ascendis Pharma A/S's EPS grew from $-2.58 (2016) to $-3.62 (2025).
Chart 5Free Cash Flow — 5 Years
Soleno Therapeutics, Inc. generated $47M FCF in 2025 (+268% vs 2021). Ascendis Pharma A/S generated $44M FCF in 2025 (+110% vs 2021).
SLNO vs ASND: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SLNO or ASND a better buy right now?
Soleno Therapeutics, Inc. (SLNO) offers the better valuation at 100.2x trailing P/E (9.3x forward), making it the more compelling value choice. Analysts rate Soleno Therapeutics, Inc. (SLNO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLNO or ASND?
On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 9.3x.
03Which is the better long-term investment — SLNO or ASND?
Over the past 5 years, Ascendis Pharma A/S (ASND) delivered a total return of +49.4%, compared to -80.3% for Soleno Therapeutics, Inc. (SLNO). A $10,000 investment in ASND five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ASND returned +1246% versus SLNO's -90.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLNO or ASND?
By beta (market sensitivity over 5 years), Ascendis Pharma A/S (ASND) is the lower-risk stock at 0.24β versus Soleno Therapeutics, Inc.'s 0.68β — meaning SLNO is approximately 189% more volatile than ASND relative to the S&P 500.
05Which has better profit margins — SLNO or ASND?
Soleno Therapeutics, Inc. (SLNO) is the more profitable company, earning 11.0% net margin versus -31.7% for Ascendis Pharma A/S — meaning it keeps 11.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLNO leads at 32.4% versus -18.9% for ASND. At the gross margin level — before operating expenses — ASND leads at 85.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SLNO or ASND more undervalued right now?
On forward earnings alone, Soleno Therapeutics, Inc. (SLNO) trades at 9.3x forward P/E versus 49.1x for Ascendis Pharma A/S — 39.8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SLNO: 169.3% to $105.20.
07Which pays a better dividend — SLNO or ASND?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SLNO or ASND better for a retirement portfolio?
For long-horizon retirement investors, Ascendis Pharma A/S (ASND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.24), +1246% 10Y return). Both have compounded well over 10 years (ASND: +1246%, SLNO: -90.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SLNO and ASND?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.